|Activity of cytotoxic agents against clear cell carcinoma of the ovary which is intrinsically platinum-refractory|
Authors: Y Shimizu, H Nagata, S Umezawa, M Nishida, Y Kikuchi, K Hasumi, T Yokokura
Affiliations: YAKULT CENT INST MICROBIOL RES,KUNITACHI,TOKYO 186,JAPAN. UNIV TSUKUBA,DEPT OBSTET & GYNECOL,IBARAKI,OSAKA,JAPAN. NATL DEF MED COLL,DEPT OBSTET & GYNECOL,TOKOROZAWA,SAITAMA 359,JAPAN.
The aim of the present study was to evaluate cytotoxic agents active for clear cell carcinoma of the ovary (OCCA) which is intrinsically platinum-resistant. We first conducted in vitro chemosensitivity tests assessing antitumor activities of Various agents against OCCA using two cell lines (HAC-2 and KK) established from ascites of patients with pure OCCA. The most potent single agent was SN-38 (active substance of CPT-11 in vivo) in both cell lines. The second most potent agent was mitomycin-C (MMC) followed by doxorubicin (DOX) in HAC-2 and DOX followed by MMC in KK, respectively. In vivo chemosensitivity test of agents on HAC-2 transplanted into BALB/C nude mice demonstrated that MMC was most potent, followed by DOX and CPT-11. Moreover, a combination of CPT-11 and MMC exhibited the highest anti-tumor activity in this animal model. Cisplatin, etoposide, and paclitaxel were found to be ineffective in either the in vitro or in vivo experimental system. Clinical trial with a combination of MMC and CPT-11 are warranted in patients with OCCA.